Stromelysin‐3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34

  title={Stromelysin‐3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34},
  author={H.‐J. Kim and J.Y. Lee and S.H. Kim and Young Joon Seo and J.H. Lee and J.‐K. Park and M.-H. Kim and Yong Woo Cinn and K‐H. Cho and Tae Young Yoon},
  journal={British Journal of Dermatology},
Background The distinction between dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) is a well‐known challenge for dermatopathologists. Immunohistochemical stains have been used to augment routine histological examination to aid in differentiating DF from DFSP. Stromelysin‐3 (ST3) is a member of the matrix metalloproteinase (MMP) family, MMP‐11, which is expressed in the skin during wound healing and in the stroma of basal cell carcinoma. Recent studies demonstrated that DFs… 
Collagen triple helix repeat containing‐1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma
Collagen triple helix repeat containing‐1 (Cthrc1) was identified as a novel gene expressed in the adventitia and neointima on arterial injury and indicated to be a cell type‐specific inhibitor of transforming growth factor‐β, which impacts collagen type I and III deposition, neointimal formation, and dedifferentiation of stem cells.
IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans
  • J. Li, Y. Yu, H. Chen
  • Medicine
    Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2012
Loss of insulin‐like growth factor‐binding protein 7 (IGFBP7) has been found to be a critical step in the development of melanoma and colon cancer and immunostaining of IGFBP7 in various dermatofibrosarcoma protuberans and dermatofIBroma has not been studied before.
Expression of MMP‐2, MMP‐9 and MMP‐11 in dermatofibroma and dermatofibrosarcoma protuberans
Immunohistology and Molecular Studies of Fibrohistiocytic and Myofibroblastic Cutaneous Tumors
The pertinent immunohistochemical and molecular features of each entity are described, together with common pitfalls and differential diagnosis clues.
Dermatofibrosarcoma protuberans (DFSP)
The tumour is equally frequent in men and women and the mortality rate is low, and often the juvenile precursor lesion of DFSP is called giant cell fibroblastoma.
Dermatofibrosarcoma protuberans.
The Immunological Roles of Periostin/Tumor-Associated Macrophage Axis in Development of Dermatofibrosarcoma Protuberans.
Examination of the cancer stroma of DFSP found dense deposits of periostin as well as a substantial number of CD163+ TAMs were detected at the peripheral areas ofDFSP, suggesting increased levels of MMP1 and MMP12 on TAMs in the peripheral area of DF SP might contribute to local invasion.
Dermatofibrosarcoma Protuberance of the Breast: a Diagnostic Challenge
A case of a DFSP of the right breast in a middle aged lady with history of recurrent breast lumps excised and diagnosed in the past as benign is reported.


Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans.
Although ST3 is a "negative" marker for DFP and therefore does not demonstrate the margins of the neoplasm, it is more reliable than CD34 staining in differentiating this tumor from a dermatofibroma.
CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
An immunoprofile using antibodies to CD34 and factor XIIIa is capable of distinguishing between DFSP and the fibrous type of DF in the vast majority of cases, as long as there is recognition that there may be some CD34-positive cells in DFs, as well as some factor-XIIIa-positive Cells in DFSPs.
Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34
CD34 expression by the tumour cells can be an extremely useful marker in establishing a definitive diagnosis of DFSP, a slow growing, locally invasive tumour whose differentiation from other fibrohistiocytic tumours sometimes poses serious diagnostic problems.
CD34 and Factor XIII a in the Differential Diagnosis of Dermatofibroma and Dermatofibrosarcoma Protuberans
When used together with other histopathological criteria, factor-XIIIa antibody and particularly CD34 may help to differentiate these two processes.
Differential expression of factor XIIIa and CD34 in cutaneous mesenchymal tumors
It is suggested that these tumors can be delineated by their relative degrees of FXIIIa and CD34 expression and that these neoplasms may be a useful link with which to study the relationship between CD34+ cells and dermal dendrocytes.
CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Assessment of the expression of standard CD44 (CD44s) and its isoforms and hyaluronate binding protein (HA) in DF and DFSP indicates that CD44 and HA can be used as additional diagnostic markers to distinguish DF from DFSP.
The expression levels and the differential expression of transforming growth factor‐β receptors in dermatofibroma and dermatofibrosarcoma protuberans
This data indicates that TGF‐β has an important role in the progression of sclerosis in fibrotic diseases and may need to be investigated further to establish a causative agent for this disease.
Stromelysin‐3 (ST‐3): immunohistochemical characterization of the matrix metalloproteinase (MMP)‐11 in benign and malignant skin tumours and other skin disorders
It is concluded that ST‐3 protein is a fibroblastic factor expressed in stromal cells adjacent to carcinoma cells, and that it does not play a role in eczema, psoriasis or virus‐induced skin lesions.